194 related articles for article (PubMed ID: 17229665)
1. Bisphosphonate treatment of tumor-induced hypercalcemia in a toddler: case report and review of related literature.
Mastrandrea LD; Albini CH
Endocr Pract; 2006; 12(6):670-5. PubMed ID: 17229665
[TBL] [Abstract][Full Text] [Related]
2. The use of pamidronate in PTHrP associated hypercalcaemia in infancy.
Buckmaster A; Rodda C; Cowell CT; Ogle G; Dorney S
J Pediatr Endocrinol Metab; 1997; 10(3):301-4. PubMed ID: 9388823
[No Abstract] [Full Text] [Related]
3. [A case of esophageal carcinoma with hypercalcemia caused by PTH-rP--the effect of therapy on the bone and calcium metabolism].
Nakayama Y; Okuno S; Miki T; Nishizawa Y; Morii H
Nihon Naibunpi Gakkai Zasshi; 1992 Dec; 68(12):1294-9. PubMed ID: 1291340
[TBL] [Abstract][Full Text] [Related]
4. Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate.
Wimalawansa SJ
Cancer; 1994 Apr; 73(8):2223-30. PubMed ID: 8156530
[TBL] [Abstract][Full Text] [Related]
5. Rhabdoid tumor of the kidney with humoral hypercalcemia and parathyroid hormone-related protein production.
Papadakis V; Vlachopapadopoulou EA; Levine L
Med Pediatr Oncol; 1995 Feb; 24(2):133-6. PubMed ID: 7990762
[TBL] [Abstract][Full Text] [Related]
6. Increased renal calcium reabsorption by parathyroid hormone-related protein is a causative factor in the development of humoral hypercalcemia of malignancy refractory to osteoclastic bone resorption inhibitors.
Onuma E; Azuma Y; Saito H; Tsunenari T; Watanabe T; Hirabayashi M; Sato K; Yamada-Okabe H; Ogata E
Clin Cancer Res; 2005 Jun; 11(11):4198-203. PubMed ID: 15930357
[TBL] [Abstract][Full Text] [Related]
7. Humoral hypercalcemia of pregnancy treated with bisphosphonates.
Koren R; Neeman O; Koren S; Benbassat CA
Arch Endocrinol Metab; 2018 Feb; 62(1):125-128. PubMed ID: 29694631
[TBL] [Abstract][Full Text] [Related]
8. Treatment of malignancy-associated hypercalcemia with YM175, a new bisphosphonate: elevated threshold for parathyroid hormone secretion in hypercalcemic patients.
Fukumoto S; Matsumoto T; Takebe K; Onaya T; Eto S; Nawata H; Ogata E
J Clin Endocrinol Metab; 1994 Jul; 79(1):165-70. PubMed ID: 8027221
[TBL] [Abstract][Full Text] [Related]
9. Tumor induced hypercalcemia in a patient with mediastinal synovial sarcoma.
Vakili R; Hiradfar M; Zabolinejad N; Badiei Z
J Pediatr Endocrinol Metab; 2007 Jul; 20(7):841-5. PubMed ID: 17849748
[TBL] [Abstract][Full Text] [Related]
10. Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy.
Rizzoli R; Thiébaud D; Bundred N; Pecherstorfer M; Herrmann Z; Huss HJ; Rückert F; Manegold C; Tubiana-Hulin M; Steinhauer EU; Degardin M; Thürlimann B; Clemens MR; Eghbali H; Body JJ
J Clin Endocrinol Metab; 1999 Oct; 84(10):3545-50. PubMed ID: 10522993
[TBL] [Abstract][Full Text] [Related]
11. Recurrent hypercalcemia due to ectopic production of parathyroid hormone-related protein and intact parathyroid hormone in a single patient with multiple malignancies.
Eid W; Wheeler TM; Sharma MD
Endocr Pract; 2004; 10(2):125-8. PubMed ID: 15256329
[TBL] [Abstract][Full Text] [Related]
12. Severe Hypercalcemia in a Child With Acute Lymphoblastic Leukemia Relapse: Successful Management With Combination of Calcitonin and Bisphosphonate.
Tagiyev A; Demirbilek H; Tavil B; Buyukyilmaz G; Gumruk F; Cetin M
J Pediatr Hematol Oncol; 2016 Apr; 38(3):232-4. PubMed ID: 26907650
[TBL] [Abstract][Full Text] [Related]
13. The coexistence of renal cell carcinoma and diffuse large B-cell lymphoma with hypercalcemic crisis as the initial presentation.
Yilmaz H; Namuslu M; Bilgic MA; Bavbek N; Akcay A
Endocr Regul; 2014 Jul; 48(3):113-9. PubMed ID: 25110209
[TBL] [Abstract][Full Text] [Related]
14. Pamidronate and calcitonin as therapy of acute cancer-related hypercalcemia in children.
Schmid I; Stachel D; Schön C; Bauer M; Haas RJ
Klin Padiatr; 2001; 213(1):30-4. PubMed ID: 11225473
[TBL] [Abstract][Full Text] [Related]
15. Therapy of hypercalcemia due to parathyroid carcinoma with intravenous dichloromethylene diphosphonate.
Shane E; Jacobs TP; Siris ES; Steinberg SF; Stoddart K; Canfield RE; Bilezikian JP
Am J Med; 1982 Jun; 72(6):939-44. PubMed ID: 6211978
[TBL] [Abstract][Full Text] [Related]
16. Hypercalcemia of malignancy with simultaneous elevation in serum parathyroid hormone--related peptide and 1,25-dihydroxyvitamin D in a patient with metastatic renal cell carcinoma.
Shivnani SB; Shelton JM; Richardson JA; Maalouf NM
Endocr Pract; 2009 Apr; 15(3):234-9. PubMed ID: 19364692
[TBL] [Abstract][Full Text] [Related]
17. Parathyroid hormone-related protein (PTHrP) does not regulate 1,25-dihydroxyvitamin D serum levels in hypercalcemia of malignancy.
Schilling T; Pecherstorfer M; Blind E; Leidig G; Ziegler R; Raue F
J Clin Endocrinol Metab; 1993 Mar; 76(3):801-3. PubMed ID: 8445039
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonate Versus Bisphosphonate and Calcitonin for the Treatment of Moderate to Severe Hypercalcemia of Malignancy.
Khan AA; Gurnani PK; Peksa GD; Whittier WL; DeMott JM
Ann Pharmacother; 2021 Mar; 55(3):277-285. PubMed ID: 32885992
[TBL] [Abstract][Full Text] [Related]
19. Renal cell carcinoma presenting with paraneoplastic hypercalcemic coma: a case report and review of the literature.
Pepper K; Jaowattana U; Starsiak MD; Halkar R; Hornaman K; Wang W; Dayamani P; Tangpricha V
J Gen Intern Med; 2007 Jul; 22(7):1042-6. PubMed ID: 17443359
[TBL] [Abstract][Full Text] [Related]
20. Hypercalcemic complication in patients with oral squamous cell carcinoma.
Iwase M; Takemi T; Manabe M; Nagumo M
Int J Oral Maxillofac Surg; 2003 Apr; 32(2):174-80. PubMed ID: 12729778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
